GTX medical developed new implantable Go-2 system for the recovery of leg motor functions and neurological control in adults with Spinal Cord Injuries (SCI) and paralysis.
The newly designed Go-2 System provides Targeted Epidural Spinal Stimulation (TESS) therapy that will improve the reconnection of the brain with paralysed muscles and traumatic spinal cord injury in individuals.
The Go-2 device consisting is designed with 16 electrodes to control pain. The first clinical trial of implantable Go-2 system in individuals is expected to be done in 2021.
The novel technology used for developing Go-2 device helps patients with more effective treatment option compared to the current standard of care for life-threatening or irreversibly debilitating diseases or conditions.
Go-2 system has been approved by US Food and Drug Administration (FDA) to promote the recovery of leg motor functions and neurological control in adults with Spinal Cord Injuries (SCI) and paralysis. This approval for GTX’ innovative therapies improves functional recovery, enhances quality of life and independence of people with spinal cord injuries.
